|
Real-time Estimate
Cboe Europe
03:34:15 2026-10-19 EDT
|
5-day change | 1st Jan Change | ||
| 124.84 CHF | +0.11% |
|
+4.10% | +13.94% |
| 12:55am | Swiss stocks - Factors to watch on October 19 | RE |
| 10-16 | Novartis ends mid-stage Fabhalta trial targeting serious kidney condition | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 288B | |||||
| 1,120B | |||||
| 616B | |||||
| 504B | |||||
| 367B | |||||
| 360B |
- Stock Market
- Stocks
- NOVN Stock
- Charts Novartis AG
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
